Early evaluation of a screen-and-treat strategy using high-risk HPV testing for Uganda: Implications for screening coverage and treatment
The hrHPV-based screen-and-treat strategy could be cost-effective in Uganda if the screening coverage and treatment adherence are at least 30% in each screening round, and if the price per test is set below 30 international dollars. The minimum required levels of screening coverage and adherence to treatment provide potential starting points for decision-makers in planning the rollout of hrHPV testing. The headroom estimates can guide the planning costs of screening infrastructure and campaigns to achieve the required coverage and treatment adherence in Uganda.
Authors
- Jurjen van der Schans (ORCID: https://orcid.org/0000-0001-6170-1191)
- Marat Sultanov (ORCID: https://orcid.org/0000-0002-5746-811X)
- Janine de Zeeuw (ORCID: https://orcid.org/0000-0002-7979-9366)
- Marcel J. W. Greuter (ORCID: https://orcid.org/0000-0001-5721-9159)
- Marlieke de Fouw (ORCID: https://orcid.org/0000-0002-4488-4886)
- Jelle Stekelenburg (ORCID: https://orcid.org/0000-0002-2732-6620)
- Jogchum Beltman (ORCID: https://orcid.org/0000-0002-0048-7360)
- Geertruida H. de Bock (ORCID: https://orcid.org/0000-0003-3104-4471)
- Jaap Koot (ORCID: https://orcid.org/0000-0002-6933-0302)
- Carolyn Nakisige (ORCID: https://orcid.org/0000-0002-1497-8056)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Leiden University Medical Center (NL)
- Medisch Centrum Leeuwarden (NL)
- Uganda Cancer Institute (UG)
Publication Details
- Journal
- Journal of Global Health
- Published
- 2024-09-20
- DOI
- https://doi.org/10.7189/jogh.14.04157
- Citations
- 2
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- European Commission